CervoMed Inc. (CRVO) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
CervoMed Inc. (CRVO) dropped -20.81% to $1.75, trading at 2% of its 52-week range ($1.6 – $10). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Placebo-controlled results of RewinD-LB clinical trial published in Alzheimer’s Research & Therapy provides further evidence of the potential of neflamapimod to slow clinical disease progression in DLB Translational rese
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -58.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CRVO today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CRVO. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, CervoMed Inc. (CRVO) ranks #959 by composite RQD confidence (29/100, grade E) and #816 by equity capitalization ($26.5M). Within this direct 5-issuer industry benchmark cohort, CRVO leads on earnings valuation at N/A trailing P/E, while CPHI leads on capital efficiency and profitability with -11.4% ROIC and -3.2% gross margin. SHPH currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with CRVO at 29/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CRVO
ACTIVE
CervoMed Inc. | E | 29/100 | — | — | -35.0% | -20.81% | $26.5M | Benchmark Subject |
| CELU Celularity Inc. (Class A) | E | 34/100 | — | 24.4% | -35.0% | -9.66% | $27.6M | /celu-vs-crvo → |
| ABVC ABVC BioPharma Inc. | E | 34/100 | — | — | -35.0% | -4.59% | $27.8M | /abvc-vs-crvo → |
| CPHI China Pharma Holdings Inc. | D | 45/100 | — | -3.2% | -11.4% | +4.84% | $28.0M | /cphi-vs-crvo → |
| SHPH Shuttle Pharmaceuticals Holdings Inc. | D | 46/100 | — | — | -35.0% | -0.19% | $24.9M | /shph-vs-crvo → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), CervoMed Inc. (CRVO) reported GAAP revenue of $4.0M (-58.9% vs. FY2024 revenue of $9.7M , and -43.9% cumulative change since FY2023) , GAAP net income of -$27.0M, operating cash flow of -$23.4M, and free cash flow of -$23.4M (-41.9% YoY). On the balance sheet, CRVO closed FY2025 with $22.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $4.0M | -$27.0M | -$23.4M | -$23.4M | $22.9M | — |
| FY2024 (FY) | 2024-12-31 | $9.7M | -$16.3M | -$16.5M | -$16.5M | $43.1M | — |
| FY2023 (FY) | 2023-12-31 | $7.1M | -$2.2M | -$7.4M | -$7.4M | — | — |
As of 2026-11-01, CervoMed Inc. (NASDAQ: CRVO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $1.75 (-20.81% 1D, market cap $26.5M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CRVO ranks #959 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CRVO carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CELU (Celularity Inc. (Class A)) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $27.6M) and ABVC (ABVC BioPharma Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $27.8M). Among the 5-stock peer group, CRVO leads on earnings multiple (N/A) while CPHI leads on capital efficiency (-11.4% ROIC).
Per CRVO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001053691), CervoMed Inc. generated $4.0M in revenue (-58.9% YoY), -$27.0M in net income, and -$23.4M in free cash flow against $22.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
CRVO last traded at $1.75 (-20.81% on volume of 1,168,894 shares), positioning the stock -31.37% below its 50-day simple moving average ($2.55) and -50.14% below its 200-day simple moving average ($3.51). Across its 52-week range of $1.60 to $10.00, CRVO sits at the 1.8% percentile with a 14-day RSI of 24.1 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.53 to $1.97).
Why CRVO Stock dropped -20.81% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.